Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion

Dr.Reddy's Laboratories

Status and phase: Completed; Phase 1

Conditions: Head Lice

Treatments: Drug: Abametapir Lotion 0.74% w/w; Other: 0.1% sodium lauryl sulfate; Other: saline 0.9%; Other: Vehicle Lotion

Study type: Interventional

Funder types: Industry

Identifiers

NCT02062073

Ha03-006

Details and patient eligibility

About

Purpose of this study will be to determine the potential of abametapir lotion to induce sensitization by repeated topical application to the healthy skin of humans under controlled conditions.

Enrollment: 238 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Are healthy (to be confirmed by medical history) males or females, 18 years of age or older;
2. In the case of females of childbearing potential, are using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom with spermicide, diaphragm with spermicide, abstinence, partner's vasectomy). Abstinence or vasectomized partner are acceptable if the female subject agrees to implement one of the other acceptable methods of birth control if her lifestyle/partner changes;
3. If female of childbearing potential, have a negative urine pregnancy test at Day 1, and are willing to submit to a pregnancy test at the end of study;
4. Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events;
5. Are of any skin type or race, providing the skin pigmentation will allow discernment of erythema;
6. Complete a patch study Medical Screening form as well as a Medical Personal History form; and
7. Read, understand, and provide signed informed consent.

Exclusion criteria

1. Have any visible skin disease at the application site which, in the opinion of the investigative personnel, will interfere with the evaluation of the test site reaction;
2. Are not willing to refrain from using topical/systemic analgesics such as aspirin (daily use of 81 mg aspirin is acceptable), Aleve, Motrin, Advil, or Nuprin for 72 hours prior to and during the study (occasional use of acetaminophen will be permitted);
3. Are using inhaled/systemic/topical corticosteroids in the 3 weeks prior to and during the study, or systemic/topical antihistamines for 72 hours prior to and during the study;
4. Are using medication which, in the opinion of the investigative personnel, will interfere with the study results, including anti-inflammatory medications;
5. Are unwilling or unable to refrain from the use of sunscreens, cosmetics, creams, ointments, lotions, or similar products on the back during the study;
6. Have psoriasis and/or active atopic dermatitis/eczema;
7. Are females who are pregnant, plan to become pregnant during the study, or are breast-feeding a child;
8. Have a known sensitivity to constituents present in the material being evaluated;
9. Have damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site;
10. Have received treatment for any type of internal cancer within 5 years prior to study entry;
11. Have a history of, or are currently being treated for skin cancer;
12. Are currently participating in any other clinical trial;
13. Have any known sensitivity to adhesives; and/or
14. Have received any investigational treatment(s) within 4 weeks prior to study entry.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

238 participants in 4 patient groups, including a placebo group

Abametapir Lotion 0.74%

Active Comparator group

Description:

0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.

Treatment:

Drug: Abametapir Lotion 0.74% w/w

Vehicle Lotion

Placebo Comparator group

Description:

0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.

Treatment:

Other: Vehicle Lotion

0.1% sodium lauryl sulfate

Other group

Description:

Concurrent control 0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.

Treatment:

Other: 0.1% sodium lauryl sulfate

Saline 0.9%

Other group

Description:

Concurrent control 0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.

Treatment:

Other: saline 0.9%